Navigation Links
Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Date:9/7/2007

- Adding Bavituximab to Standard Regimen of Androgen Deprivation and Chemotherapy Reduced Size of Formerly Resistant Tumors by More than Half -

- Data Further Confirm Bavituximab's Potential to Enhance Multiple

Combination Regimens for Cancer Therapy -

ATLANTA, and TUSTIN, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported new preclinical studies showing an equivalent of its lead antibody bavituximab significantly shrank resistant human prostate tumors in mice when added to a standard regimen of androgen deprivation and docetaxel. The study findings will be presented today at the Innovative Minds in Prostate Cancer Today (IMPaCT) Conference in Atlanta by Dr. Yi Yin, a post-doctoral fellow in the laboratory of Dr. Philip Thorpe at UT Southwestern Medical Center in Dallas.

"These exciting results mimic the real life situation facing many prostate cancer patients whose disease is failing to respond to the standard combination of androgen deprivation and chemotherapy drugs such as docetaxel," said Dr. Thorpe. "In this study of human prostate tumors in mice, we have shown that administering a bavituximab equivalent significantly enhances the tumors' response to androgen deprivation and docetaxel, with the result that these large resistant tumors shrank by an average of more than 50% over the 13-week study. These findings further strengthen the rationale for use of bavituximab as part of combination therapy regimens for the treatment of prostate cancer."

Prostate cancer is the
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. NIEHS Researchers Identify Enzyme Critical in DNA Replication
8. Stanford Researchers Find Brain Pathway of Depression in Rats
9. Researchers Discover Method for Identifying How Cancer Evades the Immune System
10. Researchers Discover Gene For Rare Skin Disorder
11. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... Nov. 9 Cardiac Scienc...in automated external defibrillator ( AED ) and ...nced revenue of $38.9 million for the third quarte...ous guidance. The Company also recorded a charge o...d a non-cash charge of $44.0 million to increase i...
(Date:11/9/2009)...Nov. 9 Boston Scientific...edule of events at the 38th annual Global Congress...uns from November 15-19 in Orlando, Florida. Resu...aturing the Company,s Urology/Gynecology products,... mid-urethral sling systems used to treat pelvic f...
(Date:11/9/2009)...NCETON, N.J., Nov. 9 Pha...t will present at the Sixth Annual Lazard Capital ... be held at the St Regis Hotel in New York City (N...sset,s President and Chief Executive Officer, will...November 18, 2009 at 3:45 PM (ET). ,, To access...
Breaking Medicine Technology:Cardiac Science Announces Third Quarter Results 2Cardiac Science Announces Third Quarter Results 3Cardiac Science Announces Third Quarter Results 4Cardiac Science Announces Third Quarter Results 5Cardiac Science Announces Third Quarter Results 6Cardiac Science Announces Third Quarter Results 7Cardiac Science Announces Third Quarter Results 8Cardiac Science Announces Third Quarter Results 9Cardiac Science Announces Third Quarter Results 10Cardiac Science Announces Third Quarter Results 11Cardiac Science Announces Third Quarter Results 12Cardiac Science Announces Third Quarter Results 13Cardiac Science Announces Third Quarter Results 14Cardiac Science Announces Third Quarter Results 15Cardiac Science Announces Third Quarter Results 16Cardiac Science Announces Third Quarter Results 17Cardiac Science Announces Third Quarter Results 18Cardiac Science Announces Third Quarter Results 19Cardiac Science Announces Third Quarter Results 20Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 2Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 3Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 4Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 5Pharmasset to Present at Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at Lazard Capital Markets Healthcare Conference 3CMPI to Host Hill Briefing Tomorrow on Follow on Biologic Drugs for Media and Congressional Staff With Reps Eshoo and Rogers 51694 1CMPI to Host Hill Briefing Tomorrow on Follow on Biologic Drugs for Media and Congressional Staff With Reps Eshoo and Rogers 51694 2Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences 28R 29 to Provide World Class Fluid Management and Liquid Powder 51692 1Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences 28R 29 to Provide World Class Fluid Management and Liquid Powder 51692 2Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences 28R 29 to Provide World Class Fluid Management and Liquid Powder 51692 3Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences 28R 29 to Provide World Class Fluid Management and Liquid Powder 51692 4Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences 28R 29 to Provide World Class Fluid Management and Liquid Powder 51692 5Michael J Fox Foundation Awards Over 242 Million for Validation of 10 Parkinsons Therapeutic Targets 4724 1Michael J Fox Foundation Awards Over 242 Million for Validation of 10 Parkinsons Therapeutic Targets 4724 2Michael J Fox Foundation Awards Over 242 Million for Validation of 10 Parkinsons Therapeutic Targets 4724 3
...phagenics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGN...roval to commence treating patients with Type 1 di...ted transdermal insulin delivery,system, TPM/Insul...ill be,Dr. Michael D, Emden, Department of Endocri...illiam Hsu, who is an Assistant Investigator in th...
...Suffering from these Diseases, LOS ANGELES, March...ia (FM) are two serious and debilitating,diseases ...ons. However,results of a new comprehensive litera...that could help alleviate symptoms for patients su... medical director of the Holtorf Medical Group,Cen...
Other Medicine Technology:Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes 2Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes 3Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia 2Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia 3
(Date:11/9/2009)...v. 9 The House version of health c...ca Act , which passed by a vote of 220-215 on Satu...ant changes to the tax code and differs in many wa... Senate version, requiring extensive reconciliatio...cial Tax Briefing on the tax provisions of the l...
(Date:11/9/2009)...President Obama,s promise to not expand abortion ...shops still concerned for poor, elderly ,, WAS...l Francis George of Chicago, president of the Unit...he November 7 decision of the U.S. House of Repres...y from paying for elective abortions. ,, In a ...
(Date:11/9/2009)...n almost equally, study finds, , , MOND...t-dissolving drug Plavix (clopidogrel) works about... clinical trials has found. , "After this study...en and women with this very important drug," said ...thrombosis at New York University Langone Medical ...
(Date:11/9/2009)...formation could boost self-esteem, researchers say...Autistic children are more likely to have handwrit...han those without autism, researchers say. , Th...lf of the study participants had autism spectrum d... normal range for perceptual reasoning on an IQ te...
(Date:11/9/2009).... 9 /PRNewswire-FirstCall/ - Hard To Treat Disease... that Novartis, a US$41 billion international heal... H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharm...of Switzerland will begin a five-year, $1 billion ...ramatically increase its investment in its China R...
Breaking Medicine News(10 mins):Health News:CCH Briefing Details Tax Provisions of House Health Care Bill 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 3Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4
...(Nasdaq: OSTE ) announced today that the Company,... results will be released Tuesday, November 6,2007...u-Akyaw, President and,Chief Executive Officer, as...ll by dialing 1-706-643-1624. Automated playback ...
...y families, LOUISVILLE, Ky., Oct. 30 On Sunday n...elevision program "Extreme Makeover: Home,Edition"...e is being,destroyed to eliminate elevated radon g... explosion will get rid of the,radon. What is rad...
...re Thursday, WASHINGTON, Oct. 30 Did you know th...ctually composed of 50% MERCURY, a,known neurotoxi...st office,and currently is not. Councilwoman Blond...s of mercury fillings and the,alternatives that ar...
...gainst colon tumors, however , , TUESDAY, ...itamin D did not lower the overall cancer death ra...ever, they did note a marked reduction in colorect... that vitamin D might help prevent malignancy. , "...
...Inc. (NYSE: ROP ) announced that it is presenting...uesday, November 6, 2007 at 1:20 PM (Central,Time)...the presentation,will be available in the "Investo...d growth company with,trailing twelve month revenu...
...IJ,Health System announced today it has received a...f Melville, NY-based FalconStor Software Inc.,(NAS...lutions., The gift will be used to create a truly... square-foot facility,which is expected to open in...
Other Medicine News:Health News:TV Show Blows up Family's Home to Eliminate Health Risks 2Health News:A Patients Right to Know: 'Silver Fillings' are 50% Mercury 2Health News:Vitamin D Won't Help Prevent Most Cancers 2Health News:Vitamin D Won't Help Prevent Most Cancers 3
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: